Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 2/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680209 | 1.00 | TRPM5 (0.38) | TRPM5HTR1ACNR1ACHEDRD5 | |
| SCHEMBL5677085 | 0.86 | TRPM5 (0.38) | TRPM5HTR1ACNR1ACHEDRD5 | |
| SCHEMBL5677082 | 0.86 | TRPM5 (0.38) | TRPM5HTR1ACNR1ACHEDRD5 | |
| SCHEMBL11895988 | 0.82 | CNR1 (0.43) | TRPM5HTR1ACNR1ACHEPYGL | |
| SCHEMBL5676943 | 0.79 | OPRM1 (0.45) | HTR1AACHEDRD2 | |
| SCHEMBL5675691 | 0.77 | SIGMAR1 (0.44) | CNR1DRD5PYGLSLC6A2SLC6A4 | |
| SCHEMBL5680214 | 0.77 | SIGMAR1 (0.44) | CNR1DRD5PYGLSLC6A2SLC6A4 | |
| SCHEMBL5675575 | 0.77 | SIGMAR1 (0.44) | CNR1DRD5PYGLSLC6A2SLC6A4 | |
| SCHEMBL5675579 | 0.77 | SIGMAR1 (0.44) | CNR1DRD5PYGLSLC6A2SLC6A4 | |
| SCHEMBL27145561 | 0.77 | TRPM5 (0.41) | TRPM5HTR1AACHEAADATDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414426-B1 | CARBOCYCLIC HYDRAZINO INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES | BIOTIE THERAPIES CORP (FI) | 2006-03-01 | — | — | EP | disclosed |
| US-20040236108-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | BIOTIE THERAPIES CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236108-A1 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases | AOC2, VCAM1, AOC3 | TRPM5 3229/4885HTR1A 2571/4885CNR1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.